ECSP21093541A - Compuestos para el tratamiento de enfermedades y trastornos asociados con braf - Google Patents
Compuestos para el tratamiento de enfermedades y trastornos asociados con brafInfo
- Publication number
- ECSP21093541A ECSP21093541A ECSENADI202193541A ECDI202193541A ECSP21093541A EC SP21093541 A ECSP21093541 A EC SP21093541A EC SENADI202193541 A ECSENADI202193541 A EC SENADI202193541A EC DI202193541 A ECDI202193541 A EC DI202193541A EC SP21093541 A ECSP21093541 A EC SP21093541A
- Authority
- EC
- Ecuador
- Prior art keywords
- braf
- disorders
- compounds
- treatment
- associated diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se adjunta resumen de la invención
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962868581P | 2019-06-28 | 2019-06-28 | |
| US202063021410P | 2020-05-07 | 2020-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21093541A true ECSP21093541A (es) | 2022-01-31 |
Family
ID=71465389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202193541A ECSP21093541A (es) | 2019-06-28 | 2021-12-28 | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11414404B2 (es) |
| EP (1) | EP3990437A1 (es) |
| JP (1) | JP7169469B2 (es) |
| KR (1) | KR102712548B1 (es) |
| CN (1) | CN114026073B (es) |
| AU (1) | AU2020302352B2 (es) |
| BR (1) | BR112021025102A2 (es) |
| CA (1) | CA3144859C (es) |
| CO (1) | CO2021017438A2 (es) |
| CR (1) | CR20210626A (es) |
| CU (1) | CU20210098A7 (es) |
| EC (1) | ECSP21093541A (es) |
| IL (1) | IL288214B2 (es) |
| MA (1) | MA56387A (es) |
| MX (1) | MX2021015903A (es) |
| PE (1) | PE20220341A1 (es) |
| PH (1) | PH12021552913A1 (es) |
| PY (1) | PY2030114A (es) |
| TW (1) | TWI817018B (es) |
| UY (1) | UY38767A (es) |
| WO (1) | WO2020261156A1 (es) |
| ZA (1) | ZA202201329B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療braf相關的疾病和失調症之化合物 |
| SI4073065T1 (sl) * | 2019-12-10 | 2025-06-30 | F. Hoffmann-La Roche Ag | Novi derivati metilkinazolinona |
| CA3158541A1 (en) * | 2019-12-10 | 2021-06-17 | Cosimo Dolente | New braf inhibitors as paradox breakers |
| CN118490818A (zh) * | 2020-04-22 | 2024-08-16 | 生物技术欧洲股份公司 | 冠状病毒疫苗 |
| IL297963A (en) | 2020-05-07 | 2023-01-01 | Adorx Therapeutics Ltd | Antagonists of the adenosine a2a receptor |
| MX2022015703A (es) * | 2020-06-09 | 2023-01-24 | Array Biopharma Inc | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf. |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| WO2022129259A1 (en) | 2020-12-18 | 2022-06-23 | F. Hoffmann-La Roche Ag | New quinazolinone derivatives |
| CN117940130A (zh) * | 2021-03-09 | 2024-04-26 | 基因泰克公司 | 用于脑癌治疗的贝伐拉非尼 |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶-1,6(2h,7h)-二酮 |
| AU2022290851A1 (en) | 2021-06-08 | 2023-11-23 | C4 Therapeutics, Inc. | Therapeutics for the degradation of mutant braf |
| CN117642166A (zh) * | 2021-06-09 | 2024-03-01 | 中外制药株式会社 | 用于癌症治疗的组合疗法 |
| JP2024522603A (ja) * | 2021-06-09 | 2024-06-21 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | (3r)-n-[2-シアノ-4-フルオロ-3-(3-メチル-4-オキソ-キナゾリン-6-イル)オキシ-フェニル]-3-フルオロ-ピロリジン-1-スルホンアミドの新規固形物 |
| IL308015A (en) * | 2021-06-09 | 2023-12-01 | Hoffmann La Roche | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
| IL312171A (en) * | 2021-11-04 | 2024-06-01 | Hoffmann La Roche | Innovative use of the quinazolinone compound for cancer treatment |
| KR20240115893A (ko) * | 2021-12-08 | 2024-07-26 | 어레이 바이오파마 인크. | N-(2-클로로-3-((5-클로로-3-메틸-4-옥소-3,4-다이하이드로퀴나졸린-6-일)아미노)-4-플루오로페닐)-3-플루오로아제티딘-1-설폰아미드의결정질 형태 |
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| TW202409040A (zh) * | 2022-07-19 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途 |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| JP2025537786A (ja) * | 2022-11-18 | 2025-11-20 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 進行性固形がんまたは転移の治療のためのbraf阻害剤としてのキナゾリノン化合物 |
| WO2024218632A1 (en) | 2023-04-17 | 2024-10-24 | Array Biopharma Inc. | Erk protein kinase inhibitors |
| IL326137A (en) | 2023-07-28 | 2026-03-01 | Cogent Biosciences Inc | PI3K inhibitors |
| WO2025153057A1 (zh) * | 2024-01-17 | 2025-07-24 | 海思科医药集团股份有限公司 | 一种含braf抑制剂的药物组合物及其在医药上的应用 |
| WO2025176139A1 (zh) * | 2024-02-20 | 2025-08-28 | 海思科医药集团股份有限公司 | 一种喹唑啉酮衍生物的晶型及其制备方法和应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| KR101190912B1 (ko) | 2003-11-19 | 2012-10-12 | 어레이 바이오파마 인크. | Mek의 헤테로시클릭 억제제 및 그의 사용 방법 |
| US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US20090118261A1 (en) | 2004-08-31 | 2009-05-07 | Astrazeneca Ab | Quinazolinone derivatives and their use as b-raf inhibitors |
| TWI441637B (zh) | 2005-05-18 | 2014-06-21 | Array Biopharma Inc | Mek雜環抑制劑及其使用方法 |
| JP2009532449A (ja) | 2006-04-05 | 2009-09-10 | アストラゼネカ アクチボラグ | 抗癌活性のある置換キナゾリン |
| WO2007113558A2 (en) | 2006-04-05 | 2007-10-11 | Astrazeneca Ab | Quinazolinone derivatives having b-raf inhibitory activity |
| JP2009534364A (ja) * | 2006-04-18 | 2009-09-24 | アストラゼネカ アクチボラグ | キナゾリン−4−オン誘導体、それらの製造方法およびそれらを含有する医薬組成物 |
| JP2010533729A (ja) | 2007-07-17 | 2010-10-28 | プレキシコン,インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
| WO2012118492A1 (en) * | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
| JP6150813B2 (ja) | 2011-11-11 | 2017-06-21 | ノバルティス アーゲー | 増殖性疾患の治療方法 |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| CA3008312A1 (en) | 2016-01-06 | 2017-07-13 | Trillium Therapeutics Inc. | Novel fluorinated quinazoline derivatives as egfr inhibitors |
| EP3558979B1 (en) | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| EP3684772B1 (en) * | 2017-09-20 | 2023-12-06 | ABM Therapeutics Corporation | Cyclic iminopyrimidine derivatives as kinase inhibitors |
| WO2019071351A1 (en) | 2017-10-12 | 2019-04-18 | Trillium Therapeutics Inc. | NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS |
| BR112020007058A2 (pt) | 2017-10-12 | 2020-10-06 | Revolution Medicines, Inc. | compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos |
| UY38349A (es) | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
| WO2020053019A1 (en) | 2018-09-14 | 2020-03-19 | Unilever N.V. | Evaluating the efficacy of leave-on cosmetic compositions to protect skin from pollutants |
| TWI817018B (zh) * | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療braf相關的疾病和失調症之化合物 |
-
2020
- 2020-06-23 TW TW109121279A patent/TWI817018B/zh not_active IP Right Cessation
- 2020-06-24 PH PH1/2021/552913A patent/PH12021552913A1/en unknown
- 2020-06-24 US US16/910,688 patent/US11414404B2/en active Active
- 2020-06-24 KR KR1020217042157A patent/KR102712548B1/ko active Active
- 2020-06-24 CA CA3144859A patent/CA3144859C/en active Active
- 2020-06-24 JP JP2021576777A patent/JP7169469B2/ja not_active Expired - Fee Related
- 2020-06-24 MA MA056387A patent/MA56387A/fr unknown
- 2020-06-24 AU AU2020302352A patent/AU2020302352B2/en active Active
- 2020-06-24 IL IL288214A patent/IL288214B2/en unknown
- 2020-06-24 WO PCT/IB2020/055992 patent/WO2020261156A1/en not_active Ceased
- 2020-06-24 MX MX2021015903A patent/MX2021015903A/es unknown
- 2020-06-24 BR BR112021025102A patent/BR112021025102A2/pt not_active Application Discontinuation
- 2020-06-24 CU CU2021000098A patent/CU20210098A7/es unknown
- 2020-06-24 EP EP20736786.3A patent/EP3990437A1/en not_active Withdrawn
- 2020-06-24 PE PE2021002078A patent/PE20220341A1/es unknown
- 2020-06-24 CN CN202080047143.1A patent/CN114026073B/zh active Active
- 2020-06-24 CR CR20210626A patent/CR20210626A/es unknown
- 2020-06-26 UY UY0001038767A patent/UY38767A/es not_active Application Discontinuation
- 2020-06-26 PY PY202002030114A patent/PY2030114A/es unknown
-
2021
- 2021-12-20 CO CONC2021/0017438A patent/CO2021017438A2/es unknown
- 2021-12-28 EC ECSENADI202193541A patent/ECSP21093541A/es unknown
-
2022
- 2022-01-27 ZA ZA2022/01329A patent/ZA202201329B/en unknown
- 2022-05-16 US US17/745,346 patent/US11634409B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| PE20220341A1 (es) | 2022-03-14 |
| CR20210626A (es) | 2022-02-08 |
| MA56387A (fr) | 2022-05-04 |
| JP7169469B2 (ja) | 2022-11-10 |
| TWI817018B (zh) | 2023-10-01 |
| AU2020302352B2 (en) | 2023-03-23 |
| CN114026073B (zh) | 2024-08-23 |
| EP3990437A1 (en) | 2022-05-04 |
| CO2021017438A2 (es) | 2022-01-17 |
| US11414404B2 (en) | 2022-08-16 |
| PY2030114A (es) | 2021-11-10 |
| TW202114996A (zh) | 2021-04-16 |
| PH12021552913A1 (en) | 2022-04-04 |
| US20200407344A1 (en) | 2020-12-31 |
| CA3144859C (en) | 2023-09-12 |
| IL288214A (en) | 2022-01-01 |
| IL288214B1 (en) | 2024-11-01 |
| CU20210098A7 (es) | 2022-06-06 |
| UY38767A (es) | 2021-01-29 |
| WO2020261156A1 (en) | 2020-12-30 |
| AU2020302352A1 (en) | 2022-01-20 |
| JP2022539056A (ja) | 2022-09-07 |
| US20220289721A1 (en) | 2022-09-15 |
| ZA202201329B (en) | 2023-09-27 |
| KR20220011712A (ko) | 2022-01-28 |
| BR112021025102A2 (pt) | 2022-01-25 |
| IL288214B2 (en) | 2025-03-01 |
| CA3144859A1 (en) | 2020-12-30 |
| CN114026073A (zh) | 2022-02-08 |
| KR102712548B1 (ko) | 2024-09-30 |
| MX2021015903A (es) | 2022-02-03 |
| US11634409B2 (en) | 2023-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280710A (en) | Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy | |
| MX2021010193A (es) | Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales. | |
| CL2021000343A1 (es) | Inhibidores peptídicos del receptor de interleucina 23 (divisional de la solicitud n° 201800128) | |
| IL286340A (en) | Topical formulations for treatment of peripheral neuropathies | |
| IL288214A (en) | Quinazolin-4-one derivatives are useful for the treatment of braf-related diseases and disorders | |
| EP3784260A4 (en) | Compositions for the treatment of skin conditions | |
| IL281244A (en) | Combination therapy for the treatment of liver disease | |
| EP3807270C0 (en) | NOVEL HETEROCYCLYL HETEROARYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | |
| HUE059638T2 (hu) | Ízületi gyulladásos betegségek kombinált kezelése | |
| MA49141A (fr) | Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau | |
| CL2022000967A1 (es) | Composiciones y métodos para el tratamiento de enfermedades hepáticas | |
| EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения | |
| EP3844156A4 (en) | TREATMENT OF LIVER DISEASES | |
| EP3790563A4 (en) | Compositions for the treatment of skin conditions | |
| EP3959213C0 (en) | PYRIMIDINE-BASED JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES | |
| IL280664A (en) | 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases | |
| EP3583113A4 (en) | USE OF TGF-ALPHA FOR THE TREATMENT OF ILLNESSES AND CONDITIONS | |
| EP3883553A4 (en) | ARYL ANILINE AND HETEROARYL ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN CANCER | |
| IL282021A (en) | Compounds and compositions for treating conditions associated with apj receptor activity | |
| IL310870A (en) | Quinazoline compounds for treatment of disease | |
| EP3866795A4 (en) | TREATMENT OF NEUROLOGICAL DISEASES | |
| EA201892265A1 (ru) | Способы лечения офтальмологических заболеваний | |
| EP3927428C0 (en) | NORKETOTIFEN FOR THE TREATMENT OF RESPIRATORY DISORDERS | |
| MA54741A (fr) | Composés thiényl-aniline destinés au traitement d'affections de la peau | |
| EP3877383A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASES |